A Phase I Clinical Trial of NKG2D-based CAR T-cells Injection for Subjects With Relapsed/Refractory NKG2DL+ Solid Tumors
Latest Information Update: 06 Dec 2023
At a glance
- Drugs KD 025-Nanjing-KAEDI-Biotech (Primary) ; KD 025-Nanjing-KAEDI-Biotech (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 24 Nov 2021 New trial record